Exploring the role of bortezomib in newly diagnosed T-ALL/T-LL patients: a phase III COG AALL1231 clinical trial
Meeting all primary and secondary endpoints BMS announces Phase III clinical results for mavacamten
The first phase Ⅲ clinical study of Kang Ning Jereh double-antibody KN046 completes all patients enrollment
Innovative drugs for treating NASH reach all primary endpoints of Phase 2a trial
Express treatment of NASH, innovative drug reaches all primary endpoints of Phase 2a trial
Dezhan Health: VGX-3100 Project Phase III Trial Reached the Primary Endpoint and All Secondary Endpoints
Genxi Bio announced the completion of the first patient enrollment in the Phase I/II registered
Express | 5 phase 3 clinical trials have all met the standards, and dual-mechanism diabetes therapy is expected to submit marketing applications this year
Express | Subcutaneous RNAi Therapy Reached All Phase 3 Clinical Endpoints, New Drug Application Has Been Submitted
Subcutaneous RNAi therapy has reached all phase 3 clinical endpoints and a new drug application has been submitted
Genxi Bio announced the completion of the first patient enrollment in the Phase I/II registered
Boan bio-new crown and antibody completed Phase I clinical all subjects into the group
All four trials of the No. and Nord agitant Weight Loss Phase III STEP project were successful
Wanchun Medicine Punablin International Multi-Center Phase 3 study reached the main endpoint and all secondary endpoints
Lancet Sub-Journal: Phase I clinical phase I of the COVID-19 DNA candidate vaccine INO-4800, triggering immunogenicity in all patients
A Microscopic Model Calculation of the Phase Diagram of Ternary Mixtures of Cholesterol and Saturated and Unsaturated Phospholipids
Nat Commun: Phase I Clinical Trials: All-Trans-Responsic acid as a target drug for pancreatic cancer substations.
Saving the lives of patients with chronic kidney disease AstraZenelan has reached the clinical end of all phase 3.
Novo Nordsomarudi Weight Loss Phase 3 STEP Project 4 trials all successful!
Lilly IL-17A inhibitor Taltz (ixekizumab) Phase 3 clinical trial reaches primary endpoint and all important secondary endpoints